Skip to main content
main-content

Latest news

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

High mental illness burden in young-onset type 2 diabetes

Hospital

Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.

No fracture risk found with canagliflozin in real-world data

Cervical hip (femoral neck) fracture

Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.

Latest headlines

17-01-2019 | Glucokinase activators | News

Hepatic glucokinase activation may improve glycemic control in type 2 diabetes

The hepatoselective glucokinase activator TTP399 reduces glycated hemoglobin levels without increasing the risk for hypoglycemia among patients with type 2 diabetes, suggest findings from the phase IIb AGATA trial.

16-01-2019 | Diabetes prevention | News

Observational data highlight importance of diabetes prevention in midlife

Individuals who maintain a blood glucose level below the diabetes threshold during middle age have a lower risk for cardiovascular disease than those who convert to diabetes during this time, observational study data show.

16-01-2019 | Obesity | News

Gastric bypass pros and cons reported for type 2 diabetes patients

Overweight and obese patients with type 2 diabetes who undergo gastric bypass have significantly lower risks for death, cardiovascular disease, and severe kidney disease than those who do not have such surgery, Swedish research shows.

Features and expert interviews

14-12-2018 | Risk factors | Feature | Article

Sleep duration: Waking up to a major metabolic risk factor

The effect of sleep duration on glucose regulation and cardiometabolic risk is becoming an increasingly high-profile issue. medwireNews takes a look at the latest evidence, which shows the gravity of the problem but also offers some solutions.

16-11-2018 | Dapagliflozin | Feature | Video

Researcher comment: DECLARE-TIMI 58

DECLARE-TIMI 58 steering committee member John Wilding talks us through the trial's findings (5:49).

10-11-2018 | Dapagliflozin | Feature | Video

Expert commentary: DECLARE-TIMI 58

Miles Fisher talks to medwireNews about the results of the dapagliflozin cardiovascular outcomes trial DECLARE-TIMI 58.

image credits